Pharmetheus increases SweDeliver commitment with new project

2022-01-03

SweDeliver industrial partner Pharmetheus has been granted financing by Vinnova for the project Subcutaneous drug delivery: PBPK-QSP model for absorption and anti-drug antibody response. An initiative that will further invigorate the company's commitment in SweDeliver.

With co-financing from Swedish innovation agency Vinnova, SweDeliver industrial partner Pharmetheus is increasing its engagement in the development of quantitative approaches to improve chances of clinical success and facilitate risk mitigation in the development of drugs intended for subcutaneous administration.

“With a combination of quantitative system pharmacology and physiologically based biopharmaceutics modeling, we aim to achieve quantitative description, translation, and prediction of pharmacological interactions and drug delivery-dependent drug disposition,” states Erik Sjögren, Senior Consultant at Pharmetheus.

Erik Sjögren, Senior Consultant, Pharmetheus
Erik Sjögren, Senior Consultant at Pharmetheus

Pharmetheus is an Uppsala-based company, offering pharmacometric services supporting drug development of compounds in all clinical phases and in all therapeutic areas. Id doing this, Pharmetheus leverage on recent advances in model-based drug development methodology.

“The administration of drugs by injection into the fat tissue under the skin is widely used in clinical medicine. Still, we need further understanding of subcutaneous formulations, which is also one of the challenges addressed by SweDeliver, and this project will further invigorate Pharmetheus's commitment in the research forum,” says Erik Sjögren.

FACTS

  • The overall aim of the SweDeliver Parenteral Drug Delivery Work package is to develop new formulations and improved delivery systems for subcutaneous drug administration.

LEARN MORE

CONTACT

Erik Sjögren, Senior Consultant
Pharmetheus
erik.sjogren@pharmetheus.com

text: Magnus Alsne, photo: Pharmetheus 

More news

Last modified: 2022-03-31